Aby J. Mathew - Jun 14, 2021 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
Exec VP & Chief Scientific Off
Signature
/s/ Aby Mathew
Stock symbol
BLFS
Transactions as of
Jun 14, 2021
Transactions value $
-$748,900
Form type
4
Date filed
6/16/2021, 08:30 PM
Previous filing
Jun 2, 2021
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $16.4K +10K +4.76% $1.64* 220K Jun 14, 2021 Direct
transaction BLFS Common Stock Sale -$389K -10K -4.54% $38.90 210K Jun 14, 2021 Direct F1, F2
transaction BLFS Common Stock Options Exercise $16.4K +10K +4.76% $1.64* 220K Jun 16, 2021 Direct
transaction BLFS Common Stock Sale -$393K -10K -4.54% $39.27 210K Jun 16, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -10K -7.26% $0.00 128K Jun 14, 2021 Common Stock 10K $1.64 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -10K -7.83% $0.00 118K Jun 16, 2021 Common Stock 10K $1.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.40 to $39.37, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.95 to $39.69, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.